


Recombinant Human IL-17A

 Catalog#:AC13085 Derived from *E.coli*

| | |
|---|--|
| DESCRIPTION | <p>Recombinant Human Interleukin-17A is produced by our E.coli expression system and the target gene encoding Gly24-Ala155 is expressed.</p> <p>Accession#:Q16552</p> <p>Known as: Interleukin-17A; IL-17; IL-17A; Cytotoxic T-Lymphocyte-Associated Antigen 8; CTLA-8; IL17A; CTLA8; IL17</p> |
| FORMULATION | Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
| SHIPPING | <p>The product is shipped at ambient temperature.</p> <p>Upon receipt, store it immediately at the temperature listed below.</p> |
| STORAGE | <p>Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.</p> <p>Reconstituted protein solution can be stored at 4-7°C for 2-7 days.</p> <p>Aliquots of reconstituted samples are stable at < -20°C for 3 months.</p> |
| RECONSTITUTION | <p>Always centrifuge tubes before opening. Do not mix by vortex or pipetting.</p> <p>It is not recommended to reconstitute to a concentration less than 100μg/ml.</p> <p>Dissolve the lyophilized protein in distilled water.</p> <p>Please aliquot the reconstituted solution to minimize freeze-thaw cycles.</p> |
| QUALITY CONTROL | <p>Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. The ED50 for this effect is 1-7 ng/ml.</p> <p>Mol Mass: 15.26 kDa AP Mol Mass: 16 kDa, reducing conditions.</p> <p>Purity: Greater than 95% as determined by reducing SDS-PAGE.</p> <p>Endotoxin: Less than 0.1 ng/μg (1 EU/μg) as determined by LAL test.</p> |
| Background | <p>Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF- alpha, it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis, and produced by rheumatoid arthritis synovium. It increases IL-6 production, induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.</p> |
|  <p>SDS-PAGE</p> <p>kDa MK R</p> <p>120</p> <p>90</p> <p>60</p> <p>40</p> <p>30</p> <p>20</p> <p>14</p> | |